![[CEL logo]](../graphics/logo.gif){kind=logo}
For information on our pharmaceutical capability, please contact Stephen Taylor.
For information on our China capability, please contact Simon Maguire.
![[Pharmaceutical]](../graphics/pharmpic.gif)
![[China]](../graphics/chinapic.gif)
Boehringer Ingelheim
Multi-product secondary plant
Shanghai, China
![[Boehringer Ingelheim secondary plant]](graphics/boeh_sec.jpg)
The new secondary pharmaceutical manufacturing and packaging facility was a major investment for liquids, solids, unit dose vials and measured dose inhalers in class C and D cleanrooms. It also included QC and analytical laboratories as well as raw materials and environmentally-controlled finished product warehousing.
CEL responsibilities
- Investment value: US$30.0M
- GMP standards
- Class C and D cleanrooms
- Built-in expansion
- Greenfield site
- Integrated team management
Key features
- Flexibility of programme to accommodate full production demands
- Work had to carried out within very short windows of opportunity
- Airflow simulation testing to achieve improvements in critical room and machine airflow patterns
- Site utility upgrade (chiller, steam and building management system)
- Integrated team including sub-contractors to ensure optimum use of resources/expertise and flexibility
Return to our pharmaceutical project experience.
Return to our pharmaceutical capability.
Return to our China project experience.
Return to our China capability.